Author: BusinessWire

– Claimed methods have applicability in the DNA tagging of pharmaceutical, nutraceutical and personal care excipients –
STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #DSCSA–Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a lead…

Contributes to Efforts to Increase Supply
ALBANY, N.Y.–(BUSINESS WIRE)–Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that the company has bee…

MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that Dr. Harry Alcorn, its Chief Medical Officer will…

– U.S. FDA designation based on an interim analysis of the phase 3 COSMIC-311 pivotal trial, in which cabozantinib demonstrated significant improvement in progression-free survival –

– Exelixis expects to submit supplementary New Drug Application in …

Implantable microdevice provides unique insight into individual and combination therapy efficacy during early-stage discovery
WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #LIFEatCRL–Charles River Laboratories International, Inc. (NYSE: CRL) today announc…

— Promotes Sharon Townson, Ph.D., to Chief Technology Officer —

— Nir London, Ph.D., Appointed to Scientific Advisory Board —

— Christine Siu Joins Board of Directors —
BOSTON–(BUSINESS WIRE)–Monte Rosa Therapeutics, a biotechnology compan…

Multi-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of BGE-117 administered daily for 12 weeks
RICHMOND, Calif.–(BUSINESS WIRE)–#aging–BioAge Labs, Inc., a clinical-stage biotechnology company deve…

BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced three upco…

– Seralutinib (GB002) and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively –

– Topline results for both ongoing Phase 2 trials e…